Novavax (NVAX) Forecasted to Post Q1 2018 Earnings of ($0.13) Per Share

Paola Ditto
Aprile 24, 2018

Novavax, Inc. (NVAX) closed its previous trading session at $1.71 with the loss of -0.58%.

Basically, a price target is an individual analyst's projection on the future price of a stock. Zacks Investment Research's price objective points to a potential upside of 35.54% from the stock's current price.

Novavax, Inc, together with its subsidiary, Novavax AB, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of recombinant nanoparticle vaccines and adjuvants.

A stock rating usually tells investors how well a stock's market value relates to what analysts think is a fair value for the stock, based on an independent evaluation of the company. JPMorgan Chase lowered Novavax from a "neutral" rating to an "underweight" rating in a research note on Monday, March 19th. Finally, B. Riley set a $2.25 target price on Novavax and gave the company a "buy" rating in a research report on Friday, January 5th. BidaskClub upgraded shares of Novavax from a "hold" rating to a "buy" rating in a report on Thursday, March 15th. Citigroup raised Novavax from a "neutral" rating to a "buy" rating in a research report on Thursday, March 1st. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and six have assigned a buy rating to the stock.

Novavax, Inc. (NVAX) has been given an average price target of $4 from analysts, according to data collected by Finviz. The stock ended last trade at 1.71 a share and the price is up more than 37.90% so far this year. Overall, 4.93 Million shares exchanged hands versus its average trading volume of 9.67 Million shares. The company has a current ratio of 2.76, a quick ratio of 2.76 and a debt-to-equity ratio of -3.12. The company has a market capitalization of $652.53, a P/E ratio of -2.71 and a beta of 2.38. The stock appeared $2.75 above its 52-week highs and is down -5.79% for the last five trades.

Novavax (NASDAQ:NVAX) last posted its quarterly earnings results on Wednesday, March 14th. Looking out over a next 5-year period, analysts expect the company to see its earnings go up by 0.00%, annually. The firm owned 296,793 shares of the biopharmaceutical company's stock after selling 53,300 shares during the quarter. During the same period in the prior year, the company posted ($0.21) EPS. research analysts forecast that Novavax will post -0.56 earnings per share for the current fiscal year.

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Finally, Schwab Charles Investment Management Inc. boosted its position in Novavax by 17.8% during the fourth quarter. Zacks Investment Research raised Novavax from a "hold" rating to a "buy" rating and set a $2.25 target price on the stock in a research report on Tuesday, April 3rd. Geode Capital Management LLC now owns 2,945,721 shares of the biopharmaceutical company's stock valued at $3,652,000 after purchasing an additional 446,318 shares during the period. Swiss National Bank increased its holdings in shares of Novavax by 21.0% in the 4th quarter. Renaissance Technologies LLC now owns 2,815,565 shares of the biopharmaceutical company's stock worth $3,491,000 after acquiring an additional 105,611 shares during the period. Teacher Retirement System of Texas increased its holdings in Novavax by 349.8% in the fourth quarter. A P/B ratio of less than 1.0 can indicate that a stock is undervalued, while a ratio of greater than 1.0 may indicate that a stock is overvalued. Fisher Asset Management LLC bought a new stake in Novavax during the fourth quarter worth approximately $179,000. Deutsche Bank AG now owns 2,567,169 shares of the biopharmaceutical company's stock worth $3,182,000 after acquiring an additional 152,974 shares during the period. Investors measure stock performance on the basis of a company's earnings power.

Altre relazioniGrafFiotech

Discuti questo articolo

Segui i nostri GIORNALE